-Parties: The plaintiffs included Boehringer Ingelheim (Canada) Ltd. and Boehringer Ingelheim International GMBH. The defendant was Laboratoire Riva Inc.

-Subject Matter: This is a patent infringement action in the Federal Court under the Patented Medicines (Notice of Compliance) Regulations, commenced by Statement of Claim filed January 9, 2025. The defendant filed a Defence and Counterclaim, and the plaintiffs filed a Reply and Defence to Counterclaim concerning, among other things, Canadian Patent No. 2,557,801. The matter is specially case-managed and remains at the pre-trial stage; the case is ongoing.

-Date: The hearing was set on June 4, 2026.

-Venue: This was a federal case before the Federal Court.

-Amount: No financial award was specified.